You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 711 Development of oncolytic adenovirus Ad5/3-E2F-D24-hTNFa-IRES-hIL2 (TILT-123) for the treatment of solid tumours – from preclinical testing to phase I clinical trials

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
711 Development of oncolytic adenovirus Ad5/3-E2F-D24-hTNFa-IRES-hIL2 (TILT-123) for the treatment of solid tumours – from preclinical testing to phase I clinical trials

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023196018
Dec 20234808
Jan 20247506
Feb 20243402
Mar 20241402
Apr 20243005
May 20245605
Jun 2024601
Jul 20242204
Aug 2024802
Sep 20241201
Oct 20242806
Nov 20243605
Dec 20241404
Jan 202550012
Feb 202512010
Mar 2025005
Apr 2025006
May 2025004
Jun 2025003
Total6410109